Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VALERIE D CALLENDER

Allopathic & Osteopathic Physicians Dermatology

NPI
1245389717
CMS profile
10749
Location
GLENN DALE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$40,083.11

114 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VALERIE D CALLENDER

NPI 1245389717 · CMS profile ID 10749

Allopathic & Osteopathic Physicians / Dermatology

GLENN DALE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245389717?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VALERIE D CALLENDER, NPI 1245389717, CMS profile ID 10749. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245389717?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). VALERIE D CALLENDER, NPI 1245389717, CMS profile ID 10749. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245389717?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
VALERIE D CALLENDER, NPI 1245389717, CMS profile ID 10749, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1245389717?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

114 matching records · $40,083.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 114 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–114 of 114.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kyowa Kirin, Inc. $26.8002/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905068371 CMS
ABBVIE INC. $25.9202/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890697673 CMS
Lilly USA, LLC $4,800.0002/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918373413 CMS
Lilly USA, LLC $45.0001/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061282926 CMS
Lilly USA, LLC $25.0001/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061282928 CMS
Lilly USA, LLC $35.0001/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061282930 CMS
EPI Health, LLC $148.9701/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960431145 CMS
Allergan, Inc. $2,670.0001/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889855533 CMS
Allergan, Inc. $96.9301/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889855535 CMS
Allergan, Inc. $684.1301/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889855537 CMS
EPI Health, LLC $2,200.0001/22/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960431143 CMS
MAYNE PHARMA INC. $22.0401/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959843303 CMS
UCB, Inc. $26.8601/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908078293 CMS
Allergan, Inc. $87.1001/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889855531 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34,477.25 133
PY2020 $17,628.23 76
PY2021 $41,662.15 76
PY2022 $40,083.11 114
PY2023 $13,078.47 87
PY2024 $19,300.15 64
PY2025 $16,669.25 72

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,967.05 5
PY2025 Principal investigator $70,769.86 30
PY2024 Principal investigator $133,862.99 74
PY2023 Principal investigator $79,120.12 14
PY2022 Recipient $65.00 1
PY2022 Principal investigator $34,611.18 10
PY2021 Recipient $4,037.00 4
PY2021 Principal investigator $86,043.04 22
PY2020 Recipient $271.64 1
PY2020 Principal investigator $155,525.69 46
PY2019 Recipient $5,175.00 1
PY2019 Principal investigator $79,444.94 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,304.10 12/19/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240512002
Principal investigator 1 Incyte Corporation $2,316.50 12/04/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511996
Principal investigator 1 Incyte Corporation $2,259.50 12/04/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240512008
Principal investigator 1 Incyte Corporation $58.00 12/01/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240512014
Recipient Regeneron Pharmaceuticals, Inc. $340.91 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184116011
Recipient Regeneron Pharmaceuticals, Inc. $225.00 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184116013
Recipient Regeneron Pharmaceuticals, Inc. $225.00 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184116015
Recipient Regeneron Pharmaceuticals, Inc. $247.50 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184116017
Principal investigator 1 Incyte Corporation $3,457.80 11/25/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511989
Principal investigator 1 Incyte Corporation $945.00 11/07/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511981
Principal investigator 1 Incyte Corporation $875.70 10/29/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511958
Principal investigator 1 Incyte Corporation $1,637.10 10/23/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511966
Principal investigator 1 Incyte Corporation $875.70 10/09/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511970
Principal investigator 1 Incyte Corporation $270.90 10/03/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511975
Recipient Regeneron Pharmaceuticals, Inc. $928.64 10/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184116009
Principal investigator 1 Incyte Corporation $1,033.20 09/12/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511950
Principal investigator 1 PFIZER INC. $12,435.00 09/09/2025 Non-covered Recipient Entity
Callender Center for Clinical Research
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228760559
Principal investigator 1 Incyte Corporation $1,637.10 08/14/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511946
Principal investigator 1 Incyte Corporation $1,820.70 08/07/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511941
Principal investigator 1 Incyte Corporation $875.70 07/10/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511935
Principal investigator 1 PFIZER INC. $3,074.99 06/27/2025 Non-covered Recipient Entity
Callender Center for Clinical Research
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228770019
Principal investigator 1 Incyte Corporation $270.90 06/19/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511913
Principal investigator 1 Janssen Research & Development, LLC $6,042.00 06/13/2025 Non-covered Recipient Entity
Callender Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175228263
Principal investigator 1 Incyte Corporation $270.90 06/12/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511919
Principal investigator 1 Incyte Corporation $5,398.20 06/05/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240511928
Principal investigator 1 Janssen Research & Development, LLC $3,021.00 05/15/2025 Non-covered Recipient Entity
Callender Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175228284
Principal investigator 1 Janssen Research & Development, LLC $9,303.00 03/21/2025 Non-covered Recipient Entity
Callender Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175228272
Principal investigator 1 Eli Lilly and Company $1,169.07 03/10/2025 Non-covered Recipient Entity
CALLENDER CENTER FOR CLINICAL RESEARCH, LLC / RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187876577
Principal investigator 1 Janssen Research & Development, LLC $1,162.00 03/04/2025 Non-covered Recipient Entity
Callender Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175228254
Principal investigator 1 Incyte Corporation $1,479.60 02/11/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240512038
Principal investigator 1 Incyte Corporation $945.00 02/05/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240512044
Principal investigator 1 Incyte Corporation $3,360.60 01/29/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240512032
Principal investigator 1 Incyte Corporation $875.70 01/17/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240512028
Principal investigator 1 Janssen Research & Development, LLC $2,324.00 01/16/2025 Non-covered Recipient Entity
Callender Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175228278
Principal investigator 1 Incyte Corporation $270.90 01/07/2025 Non-covered Recipient Entity
CALLENDER DERMATOLOGY AND COSMETIC CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240512021